Mirum Pharmaceuticals to Report Second Quarter 2021 Financial Results and Host Conference Call on August 5, 2021
July 29 2021 - 4:00PM
Business Wire
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced that
the company will report financial results for the quarter ended
June 30, 2021 on Thursday, August 5, 2021. That same day, Mirum
will host a conference call and audio webcast at 1:30 p.m. PT/4:30
p.m. ET to provide a business update.
Conference Call Details:
U.S. toll-free:
844.200.6205
International:
646.904.5544
Passcode:
097025
You may also access the call via webcast by visiting the
Investors & Media section on Mirum’s corporate website. A
replay of this webcast will be available for 30 days.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company focused on the development and
commercialization of a late-stage pipeline of novel therapies for
debilitating liver diseases. Mirum’s lead product candidate,
maralixibat, is an investigational oral drug in development for
Alagille syndrome (ALGS), progressive familial intrahepatic
cholestasis (PFIC), and biliary atresia. Mirum has submitted an NDA
for maralixibat in the treatment of cholestatic pruritus in
patients with ALGS. The NDA has been accepted for priority review
by the FDA with a PDUFA action date of September 29, 2021.
Additionally, Mirum’s marketing authorization application for the
treatment of pediatric patients with PFIC2 has been accepted for
review (validated) by the European Medicines Agency. Mirum is also
developing volixibat, also an oral ASBT-inhibitor, in primary
sclerosing cholangitis, intrahepatic cholestasis of pregnancy, and
primary biliary cholangitis. For more information, visit
MirumPharma.com.
To augment its pipeline in cholestatic liver disease, Mirum has
acquired the exclusive option to develop and commercialize two gene
therapy programs, VTX-803 and VTX-802 for PFIC3 and PFIC2,
respectively, from Vivet Therapeutics, following preclinical
evaluation and IND-enabling studies.
Follow Mirum on Twitter, Facebook, LinkedIn and Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210729005998/en/
Investor Contacts: Ian Clements, Ph.D.
ir@mirumpharma.com
Sam Martin Argot Partners 212.600.1902 ir@mirumpharma.com
Media Contact: Erin Murphy media@mirumpharma.com
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Apr 2023 to Apr 2024
